[1]陈旭东 张逸杰 韦洋.经导管二尖瓣置换治疗原发性二尖瓣反流的研究进展[J].心血管病学进展,2023,(2):137-141.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.009]
　CHEN XudongZHANG YijieWEI Yang.Transcatheter Mitral Valve Replacement in Primary Mitral Valve Regurgitation[J].Advances in Cardiovascular Diseases,2023,(2):137-141.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.009]
点击复制

经导管二尖瓣置换治疗原发性二尖瓣反流的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年2期
页码:
137-141
栏目:
综述
出版日期:
2023-02-25

文章信息/Info

Title:
Transcatheter Mitral Valve Replacement in Primary Mitral Valve Regurgitation
作者:
陈旭东1 张逸杰2 韦洋1
(1.重庆康华众联心血管病医院心外科,重庆 400000;2.武汉大学附属人民医院心内科,湖北 武汉 430000)
Author(s):
CHEN Xudong1ZHANG Yijie2WEI Yang1
(1.,Chongqing Kanghua Zhonglian Cardiovascular Disease Hospital,Chongqing 400000,China;2.Department of Cardiology,Affiliated People’s Hospital of Wuhan University,Wuhan 430000,China)
关键词:
二尖瓣反流; 经导管二尖瓣置换; 治疗
Keywords:
Mitral valve regurgitation; Transcatheter mitral valve replacement; Treatment
DOI:
10.16806/j.cnki.issn.1004-3934.2023.02.009
摘要:
二尖瓣反流（MR）是老龄化社会中最常见的心脏瓣膜疾病，由二尖瓣膜自身结构或功能改变引发的原发性MR是MR的一大类。体外循环下二尖瓣修复或置换是原发性MR的，但其适应证窄、风险高且术后并发症多。经导管二尖瓣置换术（TMVR）很大程度上解决了药物治疗无效性和手术治疗高风险性的问题，成为原发性MR治疗的重要手段。TMVR设备大多处于早期安全性评估和可行性临床试验阶段，二尖瓣结构的复杂性也使TMVR治疗方法面临诸多挑战，人工二尖瓣的密封性、持久性以及左心室流出道阻塞和潜在血栓的形成均为TMVR技术难点。现综述目前用于原发性MR治疗的各类人工二尖瓣装置及相关研究进展。
Abstract:
Mitral Valve Regurgitation (MR) is the most common valvular heart disease in the elderlyPrimary mitral valve regurgitation is a major category of MR caused by the changes of structure or function of mitral valve. Mitral valve repair or replacement under extracorporeal circulation is the gold standard for primary mitral valve regurgitation,but it has limited indications and high risk postoperative complications. Transcatheter mitral valve regurgitation (TMVR) has become an important therapy for primary mitral valve regurgitation especially for patients with drug refractory or high risk for surgery. Most TMVR devices are in the early stage of safety evaluation and feasibility clinical trials. On account of the complexity of mitral valve structure,TMVR faces many challenges,including the tightness and durability of artificial mitral valve,as well as the formation of left ventricular outflow tract obstruction and potential thrombosis. This review summarizes kinds of artificial mitral valve devices and related research progresses used in primary mitral valve regurgitation therapy currently

参考文献/References:

[1]del Forno B,de Bonis M,Agricola E,et al. Mitral valve regurgitation:a disease with a wide spectrum of therapeutic options[J]. Nat Rev Cardiol,2020,7(12):807-827.
[2]Beg F,Little SH,Faza NN. Mitral regurgitation:a contemporary review of percutaneous mitral valve repair and role of periprocedural imaging[J]. Curr Opin Cardiol,2020,35(5):482-490.
[3]Hensey M,Brown RA,Lal S,et al. Transcatheter mitral valve replacement:an update on current techniques,technologies,and future directions[J]. JACC Cardiovasc Interv,2021,14(5):489-500.
[4]叶蕴青,许海燕,李喆,等. 中国不同区域老年瓣膜性心脏病构成和病因分析[J]. 中华老年心脑血管病杂志,2019,21(7):676-682.
[5]Dufendach K,Aranda-Michel E,Sultan I,et al. Outcomes of mitral valve surgery for severe ischemic mitral regurgitation[J]. J Card Surg,2020,35(2):390-396.
[6]Apostolidou E,Maslow AD,Poppas A. Primary mitral valve regurgitation:update and review[J]. Glob Cardiol Sci Pract,2017,2017(1):e201703.
[7]Henning RJ. The current diagnosis and treatment of high-risk patients with chronic primary and secondary mitral valve regurgitation[J]. Future Cardiol,2022,18(1):67-87.
[8]Yadgir S,Johnson CO,Aboyans V,et al. Global,regional,and national burden of calcific aortic valve and degenerative mitral valve diseases,1990-2017[J]. Circulation,2020,141(21):1670-1680.
[9]Ahmed MI,Aban I,Lloyd SG,et al. A randomized controlled phase Ⅱb trial of beta(1)-receptor blockade for chronic degenerative mitral regurgitation[J]. J Am Coll Cardiol,2012,60(9):833-838.
[10]Fiorilli PN,Herrmann HC,Szeto WY. Transcatheter mitral valve replacement:latest advances and future directions[J]. Ann Cardiothorac Surg,2021,10(1):85-95.
[11]Goode D,Dhaliwal R,Mohammadi H. Transcatheter mitral valve replacement:state of the art[J]. Cardiovasc Eng Technol,2020,11(3):229-253.
[12]Schaefer A,Conradi L. Transcatheter mitral valve replacement for degenerated bioprosthetic valves and failed annuloplasty rings[J]. Surg Technol Int,2020,37:185-190. 
[13]Gheorghe LL,Mobasseri S,Agricola E,et al. Imaging for native mitral valve surgical and transcatheter interventions[J]. JACC Cardiovasc Imaging,2021,14(1):112-127.
[14]Enta Y,Nakamura M. Transcatheter mitral valve replacement[J]. Cardiol,2021,77(6):555-564.
[15]Gammie JS,Bartus K,Gackowski A,et al. Beating-heart mitral valve repair using a novel ePTFE cordal implantation device:a prospective trial[J]. J Am Coll Cardiol,2018,71(1):25-36.
[16]Coisne A,Pontana F,Tchétché D,et al. Transcatheter mitral valve replacement:factors associated with screening success and failure[J]. EuroIntervention,2019,15(11):e983-e989.
[17]Testa L,Popolo Rubbio A,Casenghi M,et al. Transcatheter mitral valve replacement in the transcatheter aortic valve replacement era[J].J Am Heart Assoc,2019,8(22):e013352.
[18]Søndergaard L,de Backer O,Franzen OW,et al. First-in-human case of transfemoral cardiAQ mitral valve implantation[J]. Circ Cardiovasc Interv,2015,8(7):e002135.
[19]Banai S,Verheye S,Cheung A,et al. Transapical mitral implantation of the Tiara bioprosthesis:pre-clinical results[J]. JACC Cardiovasc Interv,2014,7(2):154-162.
[20]Regueiro A,Ye J,Fam N,et al. 2-Year outcomes after transcatheter mitral valve replacement[J]. JACC Cardiovasc Interv,2017,10(16):1671-1678.
[21]McCarthy PM,Kislitsina ON,Malaisrie SC,et al. Transcatheter mitral valve replacement with Intrepid[J]. Interv Cardiol Clin,2019,8(3):287-294.
[22]Barbanti M,Piazza N,Mangiafico S,et al. Transcatheter mitral valve implantation using the HighLife system[J]. JACC Cardiovasc Interv,2017,10(16):1662-1670.
[23]Lamelas J,Alnajar A. Early outcomes for surgical minimally invasive SAPIEN 3 transcatheter mitral valve replacement[J]. Ann Thorac Surg,2021,112(2):494-500.
[24]Navia JL,Kapadia S,Elgharably H,et al. Transcatheter tricuspid valve implantation of NaviGate bioprosthesis in a preclinical model[J]. JACC Basic Transl Sci,2018,3(1):67-79.
[25]Walther C,Fichtlscherer S,Holubec T,et al. New developments in transcatheter therapy of mitral valve disease[J]. J Thorac Dis,2020,12(4):1728-1739.
[26]del Val D,Ferreira-Neto AN,Wintzer-Wehekind J,et al. Early experience with transcatheter mitral valve replacement:a systematic review[J]. J Am Heart Assoc,2019,8(17):e013332.
[27]Asch FM,Grayburn PA,Siegel RJ,et al. Echocardiographic outcomes after transcatheter leaflet approximation in patients with secondary mitral regurgitation:the COAPT trial[J]. J Am Coll Cardiol,2019,74(24):2969-2979.
[28]Mirabel M,Iung B,Baron G,et al. What are the characteristics of patients with severe,symptomatic,mitral regurgitation who are denied surgery?[J]. Eur Heart J,2007,28(11):1358-1365.
[29]Sorajja P,Cabalka AK,Hagler DJ,Rihal CS. Long-term follow-up of percutaneous repair of paravalvular prosthetic regurgitation[J]. J Am Coll Cardiol,2011,58(21):2218-2224.
[30]Pibarot P,Dumesnil JG. Prosthetic heart valves:selection of the optimal prosthesis and long-term management[J]. Circulation,2009,119(7):1034-1048.
[31]Guerrero M,Dvir D,Himbert D,et al. Transcatheter mitral valve replacement in native mitral valve disease with severe mitral annular calcification:results from the first multicenter global registry[J]. JACC Cardiovasc Interv,2016,9(13):1361-1371.

相似文献/References:

[1]阚通,秦永文.二尖瓣反流诊治进展[J].心血管病学进展,2015,(6):686.[doi:10.3969/j.issn.1004-3934.2015.06.008]
　KAN Tong,QIN Yongwen.Recent Progress in Diagnosis and Treatment of Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2015,(2):686.[doi:10.3969/j.issn.1004-3934.2015.06.008]
[2]马浩 张世成 宋仰午 黄思源 赵栋 凤玮.单纯冠状动脉旁路移植术治疗左心室室壁瘤的回顾性队列研究[J].心血管病学进展,2023,(5):465.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.019]
　MA Hao,ZHANG Shicheng,SONG Yangwu,et al.Surgical Effects of Coronary Artery Bypass Grafting Alone for Patients with Left Ventricular Aneurysm:A Retrospective Cohort Study[J].Advances in Cardiovascular Diseases,2023,(2):465.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.019]
[3]王湘 李刚 王水云.合并巨大左心室的心脏瓣膜病治疗现状[J].心血管病学进展,2024,(9):769.[doi:10.16806/j.cnki.issn.1004-3934.2024.09.001]
　WANG Xiang,L I Gang,WANG Shuiyun.Treatment Status of Valvular Heart Disease with Giant Left Ventricle[J].Advances in Cardiovascular Diseases,2024,(2):769.[doi:10.16806/j.cnki.issn.1004-3934.2024.09.001]

更新日期/Last Update: 2023-03-23